← All trials
NCT04863131
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 28, 2021
- Primary completion
- Jan 31, 2023
- Completion date
- Jan 31, 2023
- First posted
- Apr 28, 2021
- Last posted
- Apr 30, 2021
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fujita Health UniversityLead sponsor
- Elixirgen Therapeutics, Inc.Collaborator
- Fujita Health UniversityOverall official - principal investigator
- Fujita Health UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.